InvestSMART

Pacific Edge Limited (ASX:PEB)

ALERT: Price-sensitive ASX Announcement for PEB
Current share price for PEB : $0.230 0.09 (64.29%)+
Announcement
Release
15 Sep 2025 7:31AM
Price at Release
$0.140
Full Release
download
Summary
On 15 September 2025, Pacific Edge Limited, a cancer diagnostics company, announced that Novitas, a Medicare Administrative Contractor, plans to convene an expert panel to consider the coverage of tests, including Cxbladder Triage, in response to the 2025 update of the American Urological Association (AUA) microhematuria guideline. The panel, known as a Contractor Advisory Committee (CAC), will comprise urology experts and is expected to be convened in early 2026. The initiative aims to align Medicare policy with the updated AUA guideline. Pacific Edge supports this development, highlighting the importance of randomized controlled trials and their role in policy development. Cxbladder, a suite of non-invasive genomic urine tests used for the risk stratification of urothelial cancer, is included in the AUA guideline. The company's tests are globally available and supported by extensive research.
Key Points
  • Novitas to convene an expert panel for test coverage consideration.
  • Panel to align Medicare policy with 2025 AUA microhematuria guideline.
  • Cxbladder Triage included in the AUA guideline.
  • Expert panel to be convened in early 2026.
  • Pacific Edge supports the initiative highlighting the importance of clinical trials.
  • Cxbladder tests are globally available and supported by over 20 years of research.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.